Literature DB >> 15666089

Mycobacterial lipoarabinomannans modulate cytokine production in human T helper cells by interfering with raft/microdomain signalling.

A K Shabaana1, K Kulangara, I Semac, Y Parel, S Ilangumaran, K Dharmalingam, C Chizzolini, D C Hoessli.   

Abstract

Lipoarabinomannans (LAMs) are major lipoglycans of the mycobacterial envelope and constitute immunodominant epitopes of mycobacteria. In this paper, we show that mannose-capped (ManLAM) and non-mannose-capped (PILAM) mycobacterial lipoglycans insert into T helper cell rafts without apparent binding to known receptors. T helper cells modified by the insertion of PILAM responded to CD3 cross-linking by decreasing type 1 (IL-2 and IFN-gamma) and increasing type 2 (IL-4 and IL-5) cytokine production. Modification by the mannose-capped ManLAMs had similar, but more limited effects on T helper cell cytokine production. When incorporated into isolated rafts, PILAMs modulated membrane-associated kinases in a dose-dependent manner, inducing increased phosphorylation of Src kinases and Cbp/PAG in Th1 rafts, while decreasing phosphorylation of the same proteins in Th2 rafts. Mycobacterial lipoglycans thus modify the signalling machineries of rafts/microdomains in T helper cells, a modification of the membrane organization that eventually leads to an overall enhancement of type 2 and inhibition of type 1 cytokine production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15666089     DOI: 10.1007/s00018-004-4404-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  14 in total

1.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

2.  Non-evidence-based ICD implantations in the United States.

Authors:  Sana M Al-Khatib; Anne Hellkamp; Jeptha Curtis; Daniel Mark; Eric Peterson; Gillian D Sanders; Paul A Heidenreich; Adrian F Hernandez; Lesley H Curtis; Stephen Hammill
Journal:  JAMA       Date:  2011-01-05       Impact factor: 56.272

3.  Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.

Authors:  Patrick H Pun; Anne S Hellkamp; Gillian D Sanders; John P Middleton; Stephen C Hammill; Hussein R Al-Khalidi; Lesley H Curtis; Gregg C Fonarow; Sana M Al-Khatib
Journal:  Nephrol Dial Transplant       Date:  2014-11-17       Impact factor: 5.992

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Comparing outcome of patients with coronary artery disease and dilated cardiomyopathy in ICD and CRT recipients: data from the German DEVICE-registry.

Authors:  Kristina Wasmer; Julia Köbe; Dietrich Andresen; Ralf Zahn; Stefan G Spitzer; Joachim Jehle; Johannes Brachmann; Christoph Stellbrink; Eimo Martens; Matthias Hochadel; Jochen Senges; Helmut Klein; Lars Eckardt
Journal:  Clin Res Cardiol       Date:  2013-03-30       Impact factor: 5.460

6.  Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.

Authors:  Scott D Solomon; Steve Zelenkofske; John J V McMurray; Peter V Finn; Eric Velazquez; George Ertl; Adam Harsanyi; Jean L Rouleau; Aldo Maggioni; Lars Kober; Harvey White; Frans Van de Werf; Karen Pieper; Robert M Califf; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

7.  Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator.

Authors:  Alon Barsheshet; Arthur J Moss; David T Huang; Scott McNitt; Wojciech Zareba; Ilan Goldenberg
Journal:  J Am Coll Cardiol       Date:  2012-06-05       Impact factor: 24.094

8.  Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.

Authors:  Jeffrey S Healey; Al P Hallstrom; Karl-Heinz Kuck; Girish Nair; Eleanor P Schron; Robin S Roberts; Carlos A Morillo; Stuart J Connolly
Journal:  Eur Heart J       Date:  2007-02-05       Impact factor: 29.983

9.  Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial.

Authors:  Dietmar Bänsch; Hendrik Bonnemeier; Johan Brandt; Frank Bode; Jesper Hastrup Svendsen; Miloš Táborský; Stefan Kuster; Carina Blomström-Lundqvist; Angelika Felk; Tino Hauser; Anna Suling; Karl Wegscheider
Journal:  Eur Heart J       Date:  2015-06-25       Impact factor: 29.983

10.  Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.

Authors:  Chih-Ying Chen; Lynne Warner Stevenson; Garrick C Stewart; Deepak L Bhatt; Manisha Desai; John D Seeger; Lauren Williams; Jessica J Jalbert; Soko Setoguchi
Journal:  BMJ       Date:  2015-07-14
View more
  20 in total

1.  Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2.

Authors:  Christina L Lancioni; Qing Li; Jeremy J Thomas; XueDong Ding; Bonnie Thiel; Michael G Drage; Nicole D Pecora; Assem G Ziady; Samuel Shank; Clifford V Harding; W Henry Boom; Roxana E Rojas
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 2.  Bacterial manipulation of innate immunity to promote infection.

Authors:  Lautaro Diacovich; Jean-Pierre Gorvel
Journal:  Nat Rev Microbiol       Date:  2010-02       Impact factor: 60.633

3.  Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation.

Authors:  Robert N Mahon; Obondo J Sande; Roxana E Rojas; Alan D Levine; Clifford V Harding; W Henry Boom
Journal:  Cell Immunol       Date:  2012-03-14       Impact factor: 4.868

4.  Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection.

Authors:  J Cowan; S Pandey; L G Filion; J B Angel; A Kumar; D W Cameron
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

5.  Activation requirements and responses to TLR ligands in human CD4+ T cells: comparison of two T cell isolation techniques.

Authors:  Christina L Lancioni; Jeremy J Thomas; Roxana E Rojas
Journal:  J Immunol Methods       Date:  2009-03-09       Impact factor: 2.303

6.  Incorporation of Mycobacterium tuberculosis lipoarabinomannan into macrophage membrane rafts is a prerequisite for the phagosomal maturation block.

Authors:  Amanda Welin; Martin E Winberg; Hana Abdalla; Eva Särndahl; Birgitta Rasmusson; Olle Stendahl; Maria Lerm
Journal:  Infect Immun       Date:  2008-04-21       Impact factor: 3.441

7.  Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling.

Authors:  Robert N Mahon; Roxana E Rojas; Scott A Fulton; Jennifer L Franko; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

8.  Mannose-capped Lipoarabinomannan from Mycobacterium tuberculosis induces soluble tumor necrosis factor receptor production through tumor necrosis factor alpha-converting enzyme activation.

Authors:  Jillian M Richmond; Elizabeth R Duffy; Jinhee Lee; Kavon Kaboli; Yun Seong Kim; Daniel G Remick; Hardy Kornfeld; William W Cruikshank
Journal:  Infect Immun       Date:  2012-08-27       Impact factor: 3.441

9.  Mannose-capped lipoarabinomannan from Mycobacterium tuberculosis preferentially inhibits sphingosine-1-phosphate-induced migration of Th1 cells.

Authors:  Jillian M Richmond; Jinhee Lee; Daniel S Green; Hardy Kornfeld; William W Cruikshank
Journal:  J Immunol       Date:  2012-11-05       Impact factor: 5.422

10.  A Mycobacterium tuberculosis-derived lipid inhibits membrane fusion by modulating lipid membrane domains.

Authors:  Eri Hayakawa; Fuyuki Tokumasu; Glenn A Nardone; Albert J Jin; Vince A Hackley; James A Dvorak
Journal:  Biophys J       Date:  2007-08-17       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.